ISSN:
1546-1696
Source:
Nature Archives 1869 - 2009
Topics:
Biology
,
Process Engineering, Biotechnology, Nutrition Technology
Notes:
[Auszug] This February, New York–based Pfizer announced the acquisition of BioRexis Pharmaceutical, a biotech company in King of Prussia, Pennsylvania, with a strong product pipeline in type 2 diabetes, including long-acting agonists of glucagon-like peptide 1 (GLP-1) receptor, a key target in ...
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1038/nbt0307-263
Permalink